Epigenomics AG / Key word(s): Corporate Action
06.11.2013 08:00
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, Germany, November 6, 2013 - Epigenomics AG (ISIN: DE000A1K0516,
OTC: EPGNY) announces today that the Company successfully issued
convertible bonds with a nominal amount of EUR 500,000 to YA Global Master
SVP Ltd. ('Yorkville') excluding pre-emptive rights to existing
shareholders. The bonds were issued at 95% of their nominal amount, carry
no interest, have a term until August 5, 2014 and are convertible into up
to 112,678 shares of Epigenomics. The conversion price equals the volume
weighted average share price during a five day period prior to the time of
conversion less a 5% discount.
Further details regarding terms and conditions in connection with the
issuance of convertible bonds according to the agreement with Yorkville
were announced by the ad hoc notification dated August 18, 2013.
- End of Ad hoc -
Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and
its business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics AG is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
06.11.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
06. November 2013 - 0:00 (CEST)